Now showing items 1-1 of 1

    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, N D; Sydes, M R; Clarke, N W; Mason, M D; Dearnaley, D P; Spears, M R; Ritchie, A W S; Parker, C C; Russell, J M; Attard, G; de Bono, J; Cross, W; Jones, R J; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, A J; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, J D; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, D B; O'Sullivan, J M; Parikh, Oi; Peedell, C; Protheroe, A; Robinson, A J; Srihari, N; Srinivasan, Rajaguru; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, M K B (Elsevier, 2015-12-21)
      Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, ...